WebMD
FDA Approves Enbumyst: First and Only Nasal Spray Diuretic for Edema From Heart, Liver, and Kidney Diseases
What Is Enbumyst, and Why Does It Matter? Enbumyst is a new nasal spray form of bumetanide (first approved by the FDA in 1983). It is a type of medicine called a loop diuretic (also known as a “water ...
New Atlas
FDA approves first nasal spray diuretic for heart, liver and kidney disease
The US Food and Drug Administration (FDA) has approved the first intranasal diuretic for heart, liver and kidney disease patients, aiming to prevent a common and costly issue that results in more than ...
Business Wire
Corstasis Therapeutics Announces FDA Approval of ENBUMYST™ (bumetanide nasal spray) for the Treatment of Edema Associated with Congestive Heart Failure, Liver Disease and ...
Edema and fluid overload remain the leading causes of hospitalization and readmission for patients with CHF, cirrhosis, and chronic kidney disease. An estimated 6.7 million Americans live with heart ...
Monthly Prescribing Reference
FDA Approves Enbumyst, an Intranasal Formulation of Bumetanide
Credit: Aptar Pharma. Enbumyst is supplied in a unit-dose nasal spray containing bumetanide 0.5mg per 0.1mL. Enbumyst is not intended for chronic use and should be replaced with oral diuretics as soon ...